Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Stern IR advising them

<< Previous

Bullboard Posts

Next >>

Comment by DIYGuyon Jul 28, 2017 6:52pm

150 Views

Post# 26523981

RE:RE:RE:RE:Stern IR advising them

Maybe the reverse split should have been 50:1. Next stop super cheap financing or it's over. Great job PR firms. Could you be more useless? And that Boston office. Why?

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1